Pomalyst: payments to doctors
Payments that named Pomalyst as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3.3M
- Providers
- 8,187
- Transactions
- 32,214
- Average per transaction
- $102
The per-transaction average — $102 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 8,187 providers the average total is $400, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | $2,319,863 | 70.9% |
| Bristol Myers Squibb | $952,437 | 29.1% |